Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
Bruce Ettinger(Kaiser Permanente), Paul Lips(Amsterdam University Medical Centers), J. A. Stakkestad, Ronald K. Knickerbocker, Kristine E. Ensrud(University of Minnesota), Harry K. Genant(University of California, San Francisco), Dennis M. Black(University of California, San Francisco), Bruce Mitlak(Radius Health (United States)), Stephen Eckert(Synageva BioPharma (United States)), Pierre D. Delmas(Inserm), Claus Christiansen(Center for Clinical & Basic Research), Fredric J. Cohen, Kathryn A. Krueger, Claus C. Glüer, José Zanchetta(Universidad del Salvador), Louis V. Avioli, Thomas Nickélsen
Cited by 168
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k